article thumbnail

FDA Accepts, Grants Priority Review Designation for Bayer's msNRA for Patients with Heart Failure

DAIC

live with HF, 2 a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. 4 Approximately 6.7 million adults in the U.S. Bozkurt A, et al.

article thumbnail

Atrial Fibrillation Ablation in Heart Failure: Difference in 3-Year Outcomes between Reduced and Preserved Ejection Fraction

HeartRhythm

The coexistence of these conditions can further induce structural changes and result in worsened outcomes such as stroke, HF decompensation, poorly controlled AF, and mortality [1]. However, the real-world data on the impact of AF ablation in heart failure with preserved ejection fraction (HFpEF) is not well-established.

article thumbnail

Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP?HF II trial

European Journal of Heart Failure

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF).

article thumbnail

Is sinus rhythm maintenance after repeat catheter ablation effective in patients with atrial fibrillation and heart failure with preserved ejection fraction?

Journal of Cardiovascular Electrophysiology

Abstract Background Heart failure (HF) with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are associated with high morbidity and mortality. HFpEF were defined as HFA-PEFF score of 5 or 6 and left ventricular ejection fraction 50% before the initial CA. 423 by a log-rank test).

article thumbnail

Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial

Circulation

BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Less is known about the potential role of sodium-glucose co-transporter 2 inhibition in this high-risk population. per 100 patient-years).

article thumbnail

Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

European Journal of Heart Failure

Abstract Aims Patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) are often treated with calcium channel blockers (CCBs), although the safety of CCBs in these patients is uncertain. 0.96), while the risk of stroke was higher (HR 1.26, 95% CI 1.06–1.50)

article thumbnail

Implications of tricuspid regurgitation and right ventricular volume overload in patients with heart failure with preserved ejection fraction

European Journal of Heart Failure

Abstract Aims The aim of this study was to assess the pathophysiological implications of severe tricuspid regurgitation (TR) in patients with heart failure with preserved ejection fraction (HFpEF) by using tricuspid transcatheter edge-to-edge repair (T-TEER) as a model of right ventricular (RV) volume overload relief.